en

PRODUCT DETAIL

Ogivri 420 mg prášok na infúzny koncentrát

Code 2218D
MA number EU/1/18/1341/002
Product Form: plc ifc 1x420 mg (liek.inj.skl.)
MA Status: E - Valid centralised marketing authorisation
Type of procedure: EU
MAH, country: Biosimilar Collaborations Ireland Limited, Ireland
Therapeutic Class: 44 - CYTOSTATICA
ATC:
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XC Monoclonal antibodies
L01XC03 Trastuzumab
Shelf life: 48
Container: glass vial
Route of admin.: Intravenous use
Prescription Status: Medicinal product subject to restricted medical prescription.
Legal basis: Article 10(4) similar biological application
MA issued: 12.12.2018
SmPC + PL: European Medicines Agency's database
Safety feature Yes
Data update: 09.08.2023
eu-flag.png sk-flag.png